Related Experiment Videos
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol
G C Flaker1, J W Warnica, F M Sacks
1University of Missouri, Columbia, USA. greg_flaker@muccmail.hsc.missouri.edu
Insights
The cholesterol-lowering drug pravastatin significantly reduced cardiovascular events, including heart attack and stroke, in patients who had undergone coronary revascularization. This HMG-CoA reductase inhibitor is well-tolerated and recommended for post-procedure patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Coronary artery disease (CAD) involves atherosclerotic plaque buildup.
- HMG-CoA reductase inhibitors (statins) lower serum cholesterol and stabilize plaques.
- Patients with prior myocardial infarction (MI) are at high risk for recurrent events.
Purpose of the Study:
- To evaluate the efficacy of pravastatin in patients who have undergone coronary revascularization.
- To determine if pravastatin reduces clinical cardiovascular events in this specific patient subgroup.
- To assess the safety and tolerability of pravastatin in revascularized individuals.
Main Methods:
- Analysis of the Cholesterol and Recurrent Events (CARE) trial data.
- Inclusion of 4,159 patients with documented MI and average cholesterol levels.
- Comparison of clinical events between placebo and pravastatin groups in 2,245 revascularized patients (PTCA and CABG).
Main Results:
- Pravastatin significantly reduced the primary endpoint (CHD death or nonfatal MI) by 36% (p=0.001).
- Reductions observed in fatal/nonfatal MI (39%), repeat revascularization (18%), and stroke (39%).
- Benefits were consistent across patients who underwent percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG).
Conclusions:
- Pravastatin effectively reduces clinical cardiovascular events in post-MI patients with average cholesterol levels who have undergone revascularization.
- The therapy is well-tolerated.
- Pravastatin use should be strongly considered for most patients following coronary revascularization procedures.
Objectives:
This analysis was carried out to determine if revascularized patients derive benefit from the 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor pravastatin.
Background:
The HMG-CoA reductase inhibitors result in substantial reductions in serum cholesterol and stabilization of atherosclerotic plaques in patients with coronary artery disease.
Methods:
Pravastatin was found to reduce clinical cardiovascular events in the Cholesterol and Recurrent Events (CARE) trial consisting of 4,159 patients with a documented myocardial infarction and an average cholesterol level (mean 209 mg/dl and all <240 mg/dl). A total of 2,245 patients underwent coronary revascularization before randomization including 1,154 patients with percutaneous transluminal coronary angioplasty (PTCA) alone, 876 patients with coronary artery bypass graft (CABG) alone, and 215 patients with both procedures. Clinical events in revascularized patients were compared between patients on placebo and on pravastatin.
Results:
In the 2,245 patients who had undergone revascularization, the primary endpoint of coronary heart disease death or nonfatal myocardial infarction (MI) was reduced by 4.1% with pravastatin (relative risk [RR] reduction 36%, 95% confidence interval [CI] 17 to 51, p = 0.001). Fatal or nonfatal MI was reduced by 3.3% (RR reduction 39%, 95% CI 16 to 55, p = 0.002), postrandomization repeat revascularization was reduced by 2.6% (RR reduction 18%, 95% CI 1 to 33, p = 0.068) and stroke was reduced by 1.5% (RR reduction 39%, 95% CI 3 to 62, p = 0.037) with pravastatin. Pravastatin was beneficial in both the 1,154 PTCA patients and in the 1,091 CABG patients who had undergone revascularization before randomization.
Conclusions:
Pravastatin reduced clinical events in revascularized postinfarction patients with average cholesterol levels. This therapy was well tolerated and its use should be considered in most patients following coronary revascularization.